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Effect of Self-monitoring andMedication Self-titration
on Systolic Blood Pressure in Hypertensive Patients
at High Risk of Cardiovascular Disease
The TASMIN-SR Randomized Clinical Trial
Richard J. McManus, FRCGP; JonathanMant, MD; M. Sayeed Haque, PhD; Emma P. Bray, PhD;
Stirling Bryan, PhD; Sheila M. Greenfield, PhD; Miren I. Jones, PhD; Sue Jowett, PhD; Paul Little, MD;
Cristina Penaloza, MA; Claire Schwartz, PhD; Helen Shackleford, RGN; Claire Shovelton, PhD;
Jinu Varghese, RGN; BryanWilliams, MD; F.D. Richard Hobbs, FMedSci
IMPORTANCE Self-monitoring of blood pressure with self-titration of antihypertensives
(self-management) results in lower blood pressure in patients with hypertension, but there
are no data about patients in high-risk groups.
OBJECTIVE To determine the effect of self-monitoring with self-titration of antihypertensive
medication compared with usual care on systolic blood pressure among patients with
cardiovascular disease, diabetes, or chronic kidney disease.
DESIGN, SETTING, AND PATIENTS A primary care, unblinded, randomized clinical trial
involving 552 patients who were aged at least 35 years with a history of stroke, coronary
heart disease, diabetes, or chronic kidney disease and with baseline blood pressure of at
least 130/80 mmHg being treated at 59 UK primary care practices was conducted between
March 2011 and January 2013.
INTERVENTIONS Self-monitoring of blood pressure combined with an individualized
self-titration algorithm. During the study period, the office visit blood pressure measurement
target was 130/80mmHg and the homemeasurement target was 120/75mmHg. Control
patients received usual care consisting of seeing their health care clinician for routine blood
pressure measurement and adjustment of medication if necessary.
MAIN OUTCOMES ANDMEASURES The primary outcomewas the difference in systolic blood
pressure between intervention and control groups at the 12-month office visit.
RESULTS Primaryoutcomedatawere available from450patients (81%). Themeanbaseline
bloodpressurewas 143.1/80.5mmHg in the interventiongroupand 143.6/79.5mmHg in the
control group.After 12months, themeanbloodpressurehaddecreased to 128.2/73.8mmHg in
the interventiongroupand to 137.8/76.3mmHg in the control group, adifferenceof9.2mmHg
(95%CI, 5.7-12.7) in systolic and3.4mmHg (95%CI, 1.8-5.0) indiastolic bloodpressure following
correction for baselinebloodpressure.Multiple imputation formissing values gave similar results:
themeanbaselinewas 143.5/80.2mmHg in the interventiongroupvs 144.2/79.9mmHg in the
control group, andat 12months, themeanwas 128.6/73.6mmHg in the interventiongroupvs
138.2/76.4mmHg in the control group,with adifferenceof8.8mmHg (95%CI, 4.9-12.7) for
systolic and3.1mmHg (95%CI,0.7-5.5) for diastolic bloodpressurebetweengroups. These
resultswere comparable in all subgroups,without excessive adverse events.
CONCLUSIONS AND RELEVANCE Among patients with hypertension at high risk of
cardiovascular disease, self-monitoring with self-titration of antihypertensive medication
compared with usual care resulted in lower systolic blood pressure at 12 months.
TRIAL REGISTRATION isrctn.org Identifier: ISRCTN87171227
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E
levatedbloodpressure is the leadingrisk factor forglobal
disease burden.1 Data from national and international
surveyssuggest thatdespite improvementsover the last
decade, significant proportions of patients have poor control
of their elevated blood pressure.2-5 Using the revised Eighth
Joint National Committee (JNC 8) 2014 blood pressure
guideline,6 which proposed less restrictive targets for adults
aged60years or older and for thosewithdiabetes and chronic
kidney disease, the proportion of adults in the United States
with treatment-eligible hypertension who met blood pres-
suregoalswas less thanhalf foryoungeradults (improved from
41.2%under JNC7 to47.5%under JNC8criteria) and less than
two-thirds for older adults (although improved from40%un-
der JNC 7 to 65.8% under JNC 8).7 Most management of hy-
pertension is undertaken in primary care, where it comprises
themost common long-term condition seen by family physi-
cians, so it is appropriate that interventions are delivered in
this setting.8 Self-monitoring is now common, with approxi-
mately a third of patients with hypertension using it in the
United Kingdom and more internationally.9,10 Trials investi-
gating self-monitoring have shown promise in the reduction
of blood pressure particularly when combined with other
interventions.11
The Telemonitoring and Self-Management in Hyperten-
sion 2 (TASMINH 2) trial found that self-management, com-
prising self-monitoring with self-titration of antihyperten-
sives, resulted in significantly lower (5.4mmHg) systolicblood
pressure after 1 year thandidusual care.12However, the study
included few patients with high-risk conditions such as car-
diovascular disease, diabetes, or chronic kidney disease, in
whom the blood pressure differences appeared to be smaller,
suggesting the need for further investigation.
Thepotential advantage fromoptimalbloodpressure con-
trol in patients at higher cardiovascular risk is large because
the absolute benefit increases with absolute risk.13 Guideline
recommendations for bloodpressure lowering vary for differ-
ent high-risk groups.6,14-18 At the time of protocol develop-
ment for this study, theBritishHypertensionSocietyandother
international guidelines had suggested a blood pressure tar-
get of less than 130/80mmHg for patientswith stroke or tran-
sient ischemic attack, diabetes, stage 3 chronic kidney dis-
ease (without proteinuria), coronary heart disease, and
myocardial infarction, providing uniformity across the range
of high-risk groups.14,19
The aim of this trial was to determine whether self-
management of hypertension resulted in lower blood pres-
sure than usual care in a population of patients at high risk of
cardiovascular events.
Methods
Study Design and Population
Targets and Self-Management for the Control of Blood Pres-
sure in Stroke andatRiskGroups (TASMIN-SR)was a random-
izedunblinded trialwith automated ascertainment of thepri-
maryendpoint.Thetrialmethodshavebeendescribed indetail
elsewhere, but briefly, patients with a diagnostic Read code
(clinical code) for at least 1 of the following: stroke or tran-
sient ischemic attack; diabetes; stage 3 chronic kidney dis-
ease (estimated glomerular filtration rate, 30-59 mL/min/
m2); coronaryarterybypassgraft surgery;myocardial infarction
or angina with poorly controlled blood pressure (last re-
corded practice reading >145 mm Hg systolic) who were not
under the care of a specialist were identified by their family
physician using electronic searches of practice clinical record
systems.20Family physicians reviewed the invitation list and
excluded patients with terminal illness, patients who were
house bound, or patients they otherwise believed to be un-
suitable. The remaining potentially eligible participantswere
invited to their local clinic for a baseline examination con-
ducted by the research team in conjunctionwith the Primary
Care Research Networks in central and east England.21
Tobeeligible,patientshadtobeaged35yearsorolder,have
at least 1 of the high-risk conditions (cardiovascular disease,
diabetes, stage 3 chronic kidneydisease, or coronaryheart dis-
ease), and have a blood pressure reading during the baseline
examination of at least 130/80 mmHg. Participants were not
required to have been prescribed antihypertensive medica-
tion. Patientswere excluded if they couldnot self-monitor be-
causeof dementia or if theyhada score ofmore than 10on the
short-orientationmemory concentration test; hadbloodpres-
sure greater than 180/100mmHg; had postural hypotension,
systolicbloodpressuredropofmore than20mmHg; tookmore
than3antihypertensivemedications;wereparticipating inan-
other blood pressure study, had participated in TASMINH 2,12
or had a spousewhohad been randomized already in the cur-
rent trial; had a terminal disease;were pregnant;were receiv-
ing care for their blood pressure by a specialist rather than by
aprimary care physician; or had experienced an acute cardio-
vascular event in the previous 3 months (Figure 1).
Approvals
Ethical approval was obtained from the North West—Greater
ManchesterEastethicscommittee (reference: 10/H1013/60)and
site-specific research approval was obtained from the rel-
evant primary care organizations.
Procedures
After hearing the explanation of the study and giving written
informed consent, eligible patients were randomized be-
tweenMarch andDecember 2011 using an Internet-based sys-
tem with telephone backup to either usual care or self-
management and were followed up for 1 year. Minimization,
amethodof adaptive stratified sampling that balances thedif-
ferent groups of clinical trials simultaneously for several fac-
tors,was used to balance treatment allocation by family prac-
tice, sex, age, high-risk group, and baseline systolic blood
pressure, factorschosendueto theirpotential influenceonsys-
tolic blood pressure.22 One amendment was made following
commencement of the study to allow reminder invitations to
be sent to nonresponders. Patients randomized to usual care
bookedanappointment for a routinebloodpressure checkand
medicationreview(includingdoseadjustment if required)with
the participating family physician. Thereafter, blood pres-
sure measurement, blood pressure targets, or adjustment of
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medication for patients receiving usual care were at the dis-
cretion of the family physician.
Patients randomized to self-managementwere trained to
self-monitor bloodpressureusing avalidatedmonitor (Micro-
life Watch BP Home23) with self-titration of medication fol-
lowing a predetermined plan, in 2 or 3 sessions, each lasting
approximately an hour. Following training, intervention pa-
tients went to their family physician to agree with the indi-
vidualized 3-step plan to increase or add antihypertensive
medications. Thiswas operationalized in a paper-based algo-
rithm including the option for additional blood tests if re-
quired. Patients took their blood pressure twice each morn-
ing for the first week of eachmonth using simple color-coded
instructionsdeveloped for theTASMINH2 trial.12Fourormore
blood pressure readings recorded during the measurement
week for 2 consecutivemonths that were higher than the tar-
get necessitated a change in medication pursuant to the pre-
determined plan. Very high or very low readings (blood pres-
sure >180/100 mm Hg or <100 mm Hg systolic, eFigure 1)
required the participant to contact his/her practice. When a
medication changewas needed, patients sent a paper form to
their family physicians without any need for a consultation.
Medicationchoice remainedat thediscretionof the familyphy-
sician. If patients used all 3 steps of their management plan,
they returned to their general practitioner for additional
instructions.
Figure 1. Flow Through the Targets and Self-Management for the Control of Blood Pressure in Stroke
and High-Risk Groups (TASMIN-SR) Trial
646 Excluded
138 Withheld consent
508 Ineligible
350 Blood pressure did not meet inclusion criteria 
47 Postural hypotension
39 Not in the at-risk group
26 Taking >3 antihypertensive medication
27 Failed memory test
9 Blood pressure not managed by family physician
7 Cardiac event in last 3 mo
3 Other
3353 Excluded (housebound, terminally ill, not otherwise
recommended)a
230 Included in the primary analysis
48 Excluded from the primary analysis
46 No primary outcome
2 Randomization errors
220 Included in the primary analysis
57 Excluded from the primary analysis
56 No primary outcome
1 Randomization error
13 Withdrew between mo 6 and 12 6 Withdrew between mo 6 and 12
278 Randomized to receive usual care
276 Randomized to receive usual care
2 Randomized in error and excluded
1 Spouse already enrolled
1 Taking >3 medications
277 Randomized to receive the intervention
276 Participated in the intervention
as randomized
1 Randomized in error and excluded
(diastolic blood pressure >100 mm Hg)
6-mo Follow-up
33 Withdrew before 6-mo follow-upc
239 Attended follow-upb
6-mo Follow-up
50 Withdrew before 6-mo follow-upc
221 Attended follow-up
6210 Excluded
4207 Did not respond to invitation
2003 Declined participationb
858 Did not want to be a part of a research trial
717 Did not want to alter own medication
639 Did not want to measure their own blood pressure
379 Unable to attend primary care clinic
361 No time to participate
347 No reason given
227 Did not want to give a reason
52 High blood pressure is of no concern
7411 Invited to participate
1201 Attended baseline clinic
555 Randomized
10 764 Patients assessed for eligibility
a The breakdown of reasons for
exclusion is not known.
bPatients gavemore than 1 answer.
c Two hundred thirty-nine of 243
patients in the control group
attended the 6-month follow-up
visit. Three were unable to be
contacted and 1 had a serious illness
in the family. Two hundred
twenty-one of 226 patients in the
intervention group attended the
6-month follow-up. Twowere
unable to attend due to illness and
1 hadmoved out of the area.
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We selected blood pressure of less than 120/75 mmHg as
a target reading for the self-titration algorithms based on the
British Hypertension Society (BHS)9 and the Joint British So-
cietiesGuidelines15 for patientswith strokeor transient ische-
micattack,diabetes (in theabsenceofproteinuria), chronickid-
ney disease, or coronary heart disease.
Outcomes
The primary prespecified outcome was the difference be-
tween intervention and control in systolic blood pressure at
12 months, taking into account baseline blood pressure and
minimization factors. Patients attended 2 follow-up research
clinics at 6 and 12 months after randomization. At both base-
line and follow-up visits, blood pressure was measured by a
research facilitator systematically after 5minutes of rest using
a validated electronic automated sphygmomanometer
(Bp-TRU blood pressure M 100 or 200).24 Six blood pressure
readingswere takenat 1-minute intervals.Themeanof thesec-
ondand third readings is considered tobebest practice for ob-
taining a clinic blood pressure reading according to many in-
ternational guidelines; therefore, thiswasused for theprimary
outcome. Themain analysiswas also rerunusing themean of
the second to sixth blood pressure readings to reduce any in-
fluence of alerting effect to cuff inflation. Outcome ascertain-
ment was not blind to allocation but was determined inde-
pendently of the clinical team by a researcher using the
automatic mode of the sphygmomanometer to measure the
blood pressure without the need for intervention other than
to place the cuff on the patient and switch on the monitor to
reduce the potential for bias.
Other baseline clinical and questionnaire data were col-
lected at the same clinics.20 Prescribed medications were re-
corded from the electronic patient record with quality of life,
anxiety, and adverse effects measured using standard
questionnaires.25-27Toallowcomparisonsof theamountof an-
tihypertensivemedications taken, individual drugdoseswere
converted into defined daily doses (aWorld Health Organiza-
tion–defined assumed averagemaintenance dose per day for
a drug used for its main indication in adults).28
Statistical Analysis
Analyses were performed using STATA version 12 (Stata-
Corp). A sample size of 243 patients per group was estimated
for90%powerassuminga standarddeviationof 17mmHgand
a difference of at least 5mmHg in systolic blood pressure be-
tween interventionandcontrol groupsbasedondata fromour
previous trial.12
Assuming a 10% dropout rate during follow-up, a sample
of 270per groupwas required; a dropout rate of 20%would re-
sult inmore than85%power.Theprimaryanalysis includedall
participants who attended 12-month follow-up and had com-
plete data for the primary outcome, without imputation. A
mixed model was used to examine differences in between-
group systolic blood pressure at 12months, adjusting for base-
linebloodpressure,practice (asa randomeffect), sex,andhigh-
risk group. Sensitivity analyses examined the potential effect
of missing data including multiple imputation and replace-
mentofmissingdataby themost recentpreviousdataorby the
mean of the series. For multiple imputation, 10 multiply-
imputed data sets were generated using predictive mean-
matchingmethodsunder themissing at randomassumptions.
Planned subgroup analyseswere older vs younger (65 years as
the threshold),menvswomen, better controlled at baseline vs
worse controlled at baseline (threshold, 145 mm Hg systolic),
the different risk groups, and socioeconomic status.
Results
Of 10 764 potentially eligible patients from 59 family prac-
tices, 3353 were excluded by their family physician for being
housebound, having a terminal illness, or not being thought
suitable candidates. Of the remaining 7411 who were invited
to participate, 1201 attended a baseline clinic and were as-
sessed for eligibility.Of the2003whoprovideda reason forde-
clining invitation (> 1 answerpossible), 858 (43%)didnotwant
to take part in a trial, 717 (36%) did notwant to alter their own
medication, and639 (32%) didnotwant tomeasure their own
blood pressure. Of the 646 patients who were excluded dur-
ing the baseline examination, 350 (54%) had blood pressure
readings thatwerenotwithin the inclusion rangeand138 (21%)
withheld consent (Figure 1).
Of 555 patients randomized, 3 were randomized in error
and were immediately excluded from the study, did not re-
ceive any intervention, andwere not followed up or analyzed
further. This left 276 patients in each group. After 12 months,
220 patients in the intervention group and 230 in the control
group attended the final follow-up, providing 450 (81%) com-
plete cases for analysis. Most who dropped out did so in the
first 6months (Figure 1).Table 1 shows that the baseline char-
acteristics of participantswerewellmatchedbetweengroups.
Participants for whom outcome data were not available were
of similar age, had similar baseline blood pressure, but were
less likely to be men (eTable 1 in Supplement 2).
The primary analysis plan specified adjusted results, but
because thesewere very similar to the unadjusted results, the
latter are presented for simplicity (see eTable 2 in Supplement
2 for adjusted results). After 12months, therewas amean sys-
tolic blood pressure difference of 9.2mmHg (95%CI, 5.7-12.7)
between thegroups (Table 2).Multiple imputation formissing
values showed amarginally lowermean difference in systolic
blood pressure of 8.8mmHg (95%CI, 4.9-12.7). Further sensi-
tivity analyses by the last observation carried forward or the
meanof theseriesdidnotmateriallyaffect theprimaryoutcome
(eTable3inSupplement2).Themeanofthesecondtosixthblood
pressure readingswas almost identical to theprimary analysis
(mean difference in systolic blood pressure at 12 months,
9.1mmHg; 95%CI, 5.8-12.3; eTable 4 in Supplement 2).
After 6 months, there was a mean between-group sys-
tolic blood pressure difference of 6.1mmHg (95%CI, 2.9-9.3).
There was also a mean between-group diastolic blood pres-
suredifferenceof 3.0mmHg (95%CI, 1.4-4.7) at 6months and
3.4mmHg (95% CI, 1.8-5.1) at 12months (Table 2). Aftermul-
tiple imputation the point estimates were slightly lower: the
mean systolic between-group difference at 6 months was 5.5
mmHg (95%CI, 1.6-9.5) and themeandiastolic differencewas
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2.7 mmHg (95% CI, 0.4-5.1) at 6 months and 3.1 mmHg (95%
CI, 0.7-5.5) at 12 months. There were no significant differ-
ences in the primary outcome within any of the prespecified
subgroups (Figure 2).
Prescription of antihypertensive drugs increased in both
groups but significantly more in the intervention group: the
mean defined daily doses at 12 months for the intervention
groupwas 3.34 (95%CI, 3.1, 3.7) vs 2.61 (95%CI, 2.4-2.9) for the
control group (mean difference, 0.9; 95% CI, 0.7-1.2; Table 3,
adjusted results are presented in eTable 5 in Supplement 2).
Comparisonwith thenumberofdrugclassesprescribedshows
that this represents both an increase in dose and in the num-
ber of medications. The main changes seen were in the pre-
scriptionofcalciumchannelblockers, andthiazides,whichsig-
nificantly increased in the intervention group comparedwith
the control group (Table 3).
Although reported adverse symptoms were common in
bothgroups (Table4), therewerenosignificantdifferencesbe-
tween control and intervention groups. Additional symp-
toms that could be linked to antihypertensive treatmentwere
not significantly different between groups including dizzi-
ness, impotence, and rash. Two patients in the control group
were admitted to the hospital with chest pain, 1 on 3 occa-
sions; 3 had transient ischemic attacks; and 1 had a possible
stroke. In the intervention group, 3 patientswere admitted to
the hospital with chest pain, 2 were admitted with arrhyth-
mias, and 4 had transient ischemic attacks. One control pa-
tient and 1 intervention patient died during the study; nei-
ther death was judged to be study related.
There were no significant differences between groups in
quality of lifemeasuredby theEQ-5Dat 6or 12months (eTable
6 in Supplement 2).
Discussion
This trial has shown for the first time, to our knowledge, that
a group of high-risk individuals, with hypertension and sig-
nificant cardiovascular comorbidity, are able to self-monitor
and self-titrate antihypertensive treatment following a pre-
specifiedalgorithmdevelopedwith their familyphysicianand
that in doing so, they achieved a clinically significant reduc-
tion in systolic and diastolic blood pressure without an in-
crease in adverse events. These resultswere sustained and in-
creasingduring the 12monthsof the trial. Basedon systematic
reviews of clinical outcome trials,13 the blood pressure differ-
ence observed in those self-managing would be expected to
beassociatedwithanapproximate30%reduction instroke risk
should it be sustained.12,13
In terms of weaknesses, the follow-up of patients in the
trial was not as high as hoped. Nevertheless, primary out-
come data were available on more than 80% of participants,
and differences in blood pressure between groups were
similar whether or not missing data were accounted for in
the sensitivity analyses. Given that the trial population had
significant comorbidity, it is to be expected that loss to
follow-up would be higher than in a hypertensive popula-
tion without these comorbidities. Those lost to follow-up
were more likely to be men (especially in the intervention
group). Recruitment took place in 59 family practices over a
wide geographical area and hence logistics were complex.
Most of the dropout occurred between baseline and 6
months, particularly in the intervention group, which may
have reflected patients who felt unable to continue in the
trial once exposed to the intervention.
Table 1. Unadjusted Baseline Characteristics of 552 Patients Randomized
Usual Care
(n = 276)a
Intervention
(n = 276)a
Age, mean (SD), y 69.6 (9.7) 69.3 (9.3)
Men, No. (%) 164 (59.4) 166 (60.1)
Blood pressure, mean (SD), mm Hg
Systolic 144.2 (13.9) 143.5 (12.8)
Diastolic 79.9 (9.4) 80.2 (9.7)
Race, No. (%)
White 267 (96.7) 266 (96.4)
Black 3 (1.1) 5 (1.8)
Asian 5 (1.8) 3 (1.1)
Other 1 (0.4) 2 (0.7)
Body mass index, mean (SD)b 30.5 (5.7) 30.2 (5.0)
No. of patients 271 266
Married, No. (%) 193 (69.9) 210 (76.1)
Level of education, No. (%)
Degree or higher 34 (12.3) 30 (10.9)
School or professional certification 150 (54.4) 162 (58.7)
No qualification/not known 92 (33.3) 84 (30.4)
Occupation, No. (%)
Professional/managerial and technical 124 (44.9) 134 (48.6)
Skilled manual and nonmanual 95 (34.4) 87 (31.5)
Partly skilled and unskilled 22 (8.0) 30 (10.9)
Unemployed, unwaged, or unknown 35 (12.7) 25 (9.1)
Index of Multiple Deprivation (2007),
mean (SD)c
16.5 (11.7) 17.4 (13.6)
Current smoker, No. (%) 19 (6.9) 17 (6.2)
Anxiety score (STAI-6), mean (SD)d (n = 264)
13.9 (2.2)
(n = 270)
13.7 (2.2)
Past medical history, No. (%)
Coronary heart disease 83 (30.1) 85 (30.8)
Cerebrovascular disease 48 (17.4) 52 (18.8)
Diabetes 128 (46.4) 123 (44.6)
Chronic kidney disease 90 (32.6) 86 (31.2)
≥ Relevant comorbidities, No. (%)e 60 (21.7) 59 (21.4)
Defined daily dose, mean (SD)f 2.4 (1.8) 2.2 (1.7)
a Number of participants unless otherwise stated. Three patients (2 usual care,
1 intervention) were randomized in error and are excluded from this table (see
Figure 1).
bCalculated as weight in kilograms divided by height in meters squared.
c Index of Multiple Deprivation 2007: median for English Primary Care Trusts
23.6 with higher scores reflecting greater deprivation.
dState Trait Anxiety Inventory 6 (STAI-6; range 6-24, high scores reflect greater
anxiety) correlates with longer form Spielberger state anxiety inventory for
which an adult norm adjusted to the same scale would be 10.5.26
e Two or more from the 4 groups above.
f Defined daily dose as classified byWorld Health Organization. Figures
combine standardized “averagemaintenance dose” and number of
medications.28
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Figure 2. Blood Pressure Difference at 12Months by Subgroup for Systolic Blood Pressure
–5 10 205 15
Difference in 12-Month Blood
Pressure, Mean (95% CI), mm Hg
0
Subgroup
Comparison
P ValueAge, y
Difference in 12-Month
Blood Pressure,
 Mean (95% CI), mm Hga
No. of
Patients
149≤65 6.5 (–0.7 to 13.7)
.37
301>65 10.5 (5.4 to 15.6)
Sex
174Women 10.1 (3.4 to 16.8)
.72
276Men 8.5 (4.1 to 13.0)
Blood pressure systolic
173>145 9.8 (3.7 to 15.8)
.96
277≤145 9.6 (4.8 to 14.3)
Diabetes
246Absent 9.4 (3.8 to 15.1)
.91
204Present 8.9 (3.7 to 14.1)
Stroke or transient ischemic attack
373Absent 9.3 (4.7 to 13.8)
.96
77Present 8.9 (–1.1 to 19.1)
Chronic kidney disease
304Absent 9.5 (4.4 to 14.6)
.82
146Present 8.4 (1.1 to 15.8)
Coronary heart disease
311Absent 9.4 (4.4 to 14.4)
.88
139Present 8.7 (1.2 to 16.3)
IMD2007b
225Lower 11.6 (5.7 to 17.5)
.24
225Higher 6.6 (0.7 to 12.5)
Overall 9.2 (5.0 to 13.4)
a The difference in blood pressure
between groups at 12 months
accounts for baseline blood
pressure.
b IMD indicates the index of multiple
deprivation. Higher values
correspond to worse deprivation.
Table 2. Unadjusted Systolic and Diastolic Blood Pressure in Intervention and Usual Care Groups
Blood Pressure, mm Hg
Differenceb
Baseline 6 Month 12 Month
No. of
Patients
Mean
(95% CI)a
No. of
Patients
Mean
(95% CI)a
No. of
Patients
Mean
(95% CI)a 6 Month 12 Month
Systolic Blood Pressure Complete Case
Usual care 230 143.6
(141.9-145.4)
225c 138.1
(136.0-140.3)
230 137.8
(135.4-140.3) 6.1
(2.9-9.3)
9.2
(5.7-12.7)Intervention 220 143.1
(141.4-144.9)
215 131.8
(129.6-134.1)
220 128.2
(125.9-130.4)
Systolic Blood Pressure With Multiple Imputation for Missing Values
Usual care 276 144.2
(142.3-146.1)
276 138.4
(136.3-140.5)
276 138.2
(136.1-140.2) 5.5
(1.6-9.5)
8.8
(4.9-12.7)Intervention 276 143.5
(141.6-145.4)
276 132.1
(129.8-134.4)
276 128.6
(126.5-130.7)
Diastolic Blood Pressure Complete Case
Usual care 230 79.5
(78.3-80.8)
225c 77.2
(75.9-78.5)
230 76.3
(75.0-77.6) 3.0
(1.4-4.7)
3.4
(1.8-5.1)Intervention 220 80.5
(79.2-81.8)
215 75.3
(74.0-76.6)
220 73.8
(72.6-75.0)
Diastolic Blood Pressure With Multiple Imputation for Missing Valuesa
Usual care 276 79.9
(78.8-81.1)
276 77.6
(76.4-78.8)
276 76.4
(75.1-77.7) 2.7
(0.4-5.1)
3.1
(0.7-5.5)Intervention 276 80.2
(79.1-81.4)
276 75.2
(73.9-76.4)
276 73.6
(72.4-74.8)
aMean of second and third blood pressure readings.
bBlood pressure difference between intervention and usual care groups taking
into account baseline difference.
c Blood pressure data unavailable for one person who attended sixth month
follow-up.
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Included patientsweremostlywhite, fromaprofessional
or skilledmanual background, andwere prescribed 3 or fewer
antihypertensives, which might limit generalizability. Ran-
domizedgroupswere similarwith small differences in comor-
bidities in favor of the intervention group. No difference in
blood pressure reduction from the intervention was seen be-
tween the subgroups examined, but this may reflect inad-
equate statistical power. Any practice effects were taken into
account in the randomization and method of analysis. Indi-
vidual randomization and dropouts from the intervention
group could have caused contamination between the groups,
but thiswould have biased the results toward no effect. Simi-
larly, high-performingpractices takingpart in researchwould
have also mitigated against the observed effect.
Relatively small proportions of those potentially eligible
to take part were eventually randomized. Family physicians
could exclude patients from invitation to the trial who were
housebound, had terminal illness, or whowere thought to be
unsuitable, which is likely to have included frailer patients.
Nevertheless, those included were older (mean age 70 years)
andhadmore comorbidities thanourpreviouswork (22%had
2 ormore strokes, coronary heart disease, diabetes or chronic
kidney disease). As with TASMINH 2, only approximately 8%
of those invited to takepartwere randomized.Responses from
more than 2000 of those who declined suggest that nonre-
sponse reflected a combination of not wishing to take part in
a trial and not wishing to self-manage. More than double the
number randomized were prepared to self-manage as mea-
suredby those attending eligibility screening, andof those ex-
cluded, controlled blood pressure was the commonest rea-
son. Taken together, for patients outside of a trial situation,
we estimate that the interventionmight be suitable for about
20%. The study was unblinded but ascertainment of out-
comewas by automated sphygmomanometer, which did not
require research facilitator input other than to fit the cuff to
the patient and switch on the monitor. The potential for the
intervention group to become habituated to blood pressure
measurementwas lessened by the use of the BP-TRUmonitor
(which takes 6 readings at a time) for all study end points in
both randomization groups and the fact that the primary out-
comewasalmost identicalwhether themeanof thesecondand
third or second to sixth blood pressure readings was used.
Patients in the interventiongroupwereusinghometargets
basedon the then recommendedclinic targetof 130/80mmHg
for all 4 groups.17,19 In the interveningyears, target recommen-
dationshavetendedtorollbacktoward140/90mmHgorhigher
for most conditions although UK stroke guidelines and those
fordiabetes in thepresenceof renal disease remainequivalent
Table 3. Unadjusted Prescription of Antihypertensives (Number and Defined Daily Dose) in Intervention and Usual Care Groupsa
Time Point
Difference Between
Intervention and ControlBaseline 6 Month 12 Month
No. of
Patients
Mean
(95% CI)
No. of
Patients
Mean
(95% CI)
No. of
Patients
Mean
(95% CI) 6 Month 12 Month
No. of Antihypertensive Drugs
Usual care 230 1.63
(1.46 to 1.79)
226 1.75
(1.58 to 1.92)
230 1.73
(1.56 to 1.91) 0.19
(−0.01 to 0.39)
0.27
(0.07 to 0.47)Intervention 220 1.59
(1.42 to 1.76)
215 2.07
(1.87 to 2.26)
220 2.22
(2.03 to 2.42)
Overall Defined Daily Dose
Usual care 230 2.34
(2.10 to 2.58)
226 2.57
(2.33 to 2.81)
230 2.61
(2.37 to 2.85) 0.66
(0.17 to 1.15)
0.91
(0.42 to 1.40)Intervention 220 2.16
(1.91 to 2.40)
215 3.05
(2.80 to 3.30)
220 3.34
(3.09 to 3.59)
Defined Daily Dose Thiazides
Usual care 230 0.23
(0.17 to 0.29)
226 0.24
(0.18 to 0.30)
230 0.23
(0.17 to 0.29) 0.11
(0.02 to 0.24)
0.16
(0.04 to 0.29)Intervention 220 0.23
(0.17 to 0.30)
215 0.35
(0.29 to 0.42)
220 0.39
(0.33 to 0.46)
Defined Daily Dose Calcium Channel Blockers
Usual care 230 0.43
(0.33 to 0.53)
226 0.52
(0.42 to 0.62)
230 0.55
(0.44 to 0.65) 0.23
(0.03 to 0.44)
0.28
(0.08 to 0.49)Intervention 220 0.46
(0.36 to 0.57)
215 0.79
(0.68 to 0.89)
220 0.86
(0.75 to 0.96)
Defined Daily Dose Angiotensin-Converting Enzyme Inhibitor/Angiotensin II Receptor Blockers
Control 1.42
(1.24 to 1.60)
226 1.55
(1.37 to 1.73)
230 1.59
(1.41 to 1.77) 0.26
(−0.11 to 0.62)
0.34
(−0.02 to 0.70)Intervention 1.22
(1.04 to 1.41)
215 1.61
(1.43 to 1.80)
220 1.74
(1.55 to 1.92)
Defined Daily Dose β-Blockers
Usual care 230 0.15
(0.11 to 0.19)
226 0.15
(0.11 to 0.19)
230 0.14
(0.10 to 0.18) 0.03
(−0.05 to 0.11)
0.02
(−0.06 to 0.09)Intervention 220 0.14
(0.10 to 0.18)
215 0.17
(0.13 to 0.21
220 0.15
(0.11 to 0.19)
a Defined daily dose as classified byWorld Health Organization. Figures combine standardized “averagemaintenance dose” and number of medications.28
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to thoseused inthetrial.14Patients inthecontrolgroupreceived
usual carewithout specificationof target,whichmayhave ac-
centuatedthedifferencebetweengroupsgiventhattheachieved
mean blood pressure in the control groupwas 138/76mmHg.
Threeprevious trialshaveconsideredself-monitoringwith
self-titration of antihypertensives.12,29,30 Two trials, includ-
ing our previous study, showed reduction of blood pressure
through self-monitoring with self-titration.12,29 The third,
which used a cluster design, found that a web-based self-
titration intervention increasedbloodpressuremonitoringbut
did not affect blood pressure.30
The current study achieved a greater blood pressure re-
duction than seen previously and seems to have been medi-
ated throughgreateruseofmedication in the intervention rep-
resenting both an increase in dose and in number of
antihypertensivemedications. Increaseswereparticularlyob-
served in the use of thiazide diuretics and calcium channel
blockers comprisingadifferenceof almost 1defineddailydose
between randomized groups.28 Adherence to study medica-
tion—difficult toascertainaccuratelyandtypicallyhigh instud-
ies such as this—was not measured, but the observed differ-
ence of 9mmHgsystolic bloodpressure seenbetweengroups
is what would be expected for this degree of medication
intensification.13,31
A recently published systematic review found no other
self-titration trials but showed a range of blood pressure re-
ductions from interventions combining self-monitoringwith
additional support compared with usual care in other high-
quality trials.11 For these studies at the 12-month follow-up,
therewas consistentbenefitwithameannet reduction inboth
systolic blood pressure (range, −2.1 to −8.3 mmHg), diastolic
bloodpressure (range, 0.0 to−4.4mmHg), or both. Theblood
pressure differences from the current study are at the upper
end of these values and broadly equivalent to that achieved
inother trialsof self-monitoringcombinedwithbehavioral self-
management or a web-based intervention and additional
pharmacist care.32,33
Conclusions
This study has shown that self-monitoring with self-titration
of antihypertensives is feasible and achievable in a high-risk
populationwithoutspecial equipmentandbyfollowingamod-
est amount of training and additional family physician input.
This is a population with the most to gain in terms of reduc-
ing future cardiovascular events from optimized blood pres-
sure control. Furthermore, despite the significantly reduced
blood pressure, no additional adverse events were observed.
Validated semiautomated blood pressure monitors are now
widely available, costing as little as US $25 (£15, €18), mean-
ing that with training delivered by nurses, this intervention
could be implemented widely. At least 30% of patients with
hypertension are already self-monitoring in the United King-
domandmore internationally,10andthere isasignificantpreva-
lence of comorbidities,34 suggesting that self-management
could be appropriate for many individuals, notwithstanding
the issues discussed concerning generalizability.
Among hypertensive patients at high risk of cardiovascu-
lar disease, self-monitoring with self-titration of antihyper-
tensive medication, compared with usual care, resulted in
lower systolicbloodpressureat 12months.Patients athigh risk
of cardiovascular disease whose blood pressure is not opti-
mally controlled could be considered for self-management.
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